Some key takeaways from the Conference Call.
1) 20,000 doses ready to be distributed which is the inventory for one year. Each does costs $35,000.
Assuming that 80% of that will be paying customers we will have a revenue of $560 Million for the first year.
2) Rollout will begin on May 6th.
3) Secured BCG supply for one year and have other options in place incase of supply issues.
4) 23 Global sites activated for international expansion.
5) All International Strategic Partners have shown great interest.
6) $240Million cash on hand. Sufficient until revenue generation. No additional funding needed.
7) Front ran most financial commitments, Moonshot, CMC and Inventory buildup behind us.
8) 54 new Sales and Marketing Access Team hired, trained and Certified for 5 sales regions in the US.
9) Lunch with major presence in San Antonio, TX (beginning of May) and Chicago, IL (beginning of June)
10) Improved results from the completed Phase II non-small lung cancer trail. This may fast track FDA registration and hopefully approval.
Did I miss anything!?
Have been in this company for years and increased my bag significantly in the beginning of this year.
Now will just sit back and watch this company crush cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
